Skip to content
contact@indiamedicine.orgLogin / Register
IMSDA
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
Search for:
Menu Close
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us

WHO

  1. Home>
  2. News>
  3. WHO

Understanding WHO Prequalification for Indian Generic Medicines: A Buyer’s Guide

  • Post published:July 5, 2026
  • Post category:Knowledge

For international buyers, healthcare professionals, and procurement specialists, navigating the quality assurance landscape of generic medicines can be complex. One of the most globally recognized benchmarks for pharmaceutical quality is…

Continue Reading Understanding WHO Prequalification for Indian Generic Medicines: A Buyer’s Guide

India Pharma 2026: CDSCO Fast-Track Trials, Biosimilar Guidelines, and Innovation Agenda

  • Post published:June 27, 2026
  • Post category:News

The Indian pharmaceutical sector is undergoing a significant transformation in 2026, driven by landmark regulatory reforms from the Central Drugs Standard Control Organization (CDSCO), new clinical trial fast-track rules, updated…

Continue Reading India Pharma 2026: CDSCO Fast-Track Trials, Biosimilar Guidelines, and Innovation Agenda

How to Verify GMP Compliance of Indian Generic Medicine Manufacturers: A 2026 Buyer’s Guide

  • Post published:June 24, 2026
  • Post category:Knowledge

India, known as the "Pharmacy of the World," supplies over 20% of the global generic medicine market by volume. But with this position comes a critical responsibility — maintaining rigorous…

Continue Reading How to Verify GMP Compliance of Indian Generic Medicine Manufacturers: A 2026 Buyer’s Guide

India’s Generic Medicine Supply Chain: NITI Aayog Warns of Critical Chinese API Dependence

  • Post published:June 24, 2026
  • Post category:Knowledge

India’s pharmaceutical industry supplies roughly 40 percent of the United States’ generic medicines and approximately 20 percent of global demand. Yet behind this impressive export footprint lies a structural vulnerability…

Continue Reading India’s Generic Medicine Supply Chain: NITI Aayog Warns of Critical Chinese API Dependence
  • 1
  • 2
  • 3
  • 4
  • 5
  • Go to the next page

Recent Posts

  • India Pharma July 2026: CETA Effect, FDA Filings Lead, Market Grows 16%
    July 14, 2026/
    0 Comments
  • Understanding WHO Prequalification for Indian Generic Medicines: A Buyer’s Guide
    July 5, 2026/
    0 Comments
  • Indian Pharma Exports Rise 6.6%: Nifty Pharma Hits Record High in 2026
    July 4, 2026/
    0 Comments

Follow Us

IMSDA

Recent Posts

  • India Pharma July 2026: CETA Effect, FDA Filings Lead, Market Grows 16%
  • Understanding WHO Prequalification for Indian Generic Medicines: A Buyer’s Guide
  • Indian Pharma Exports Rise 6.6%: Nifty Pharma Hits Record High in 2026
  • India’s Generic Drug Quality Revolution: Schedule M and CDSCO Audit Guide 2026
  • India Pharma Mid-2026: FDA Filings Lead China, API Prices Drop, Biosimilars Rise

Contact Info

  • If you want to touch more medicine sales and distribution resources, you could contact us, or join us.
  • Address:2nd Floor, Bhavani CHS, Dadar West, Mumbai, 400028, Maharashtra.
  • Phone:+91 8048111688
  • Email:contact@indiamedicine.orgOpens in your application
  • Website:https://indiamedicine.org/
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
© Copyright All Right Reserve